

29. The method according to claim 26, wherein the expression system comprises an expression cassette comprising two nucleic acids encoding a different neurotrophic factor and under the control of a single transcriptional promoter.

30. The method according to claim 27, wherein the neurotrophic factor is GDNF, CNTF, BDNF or NT3.

31. The method according to claim 28, wherein the neurotrophic factors are selected from the group consisting of GDNF, CNTF, BDNF and NT3.

32. The method according to claim 31, wherein the neurotrophic factors are CNTF and GDNF.

33. The method according to claim 27, wherein the expression cassette is part of a vector.

34. The method according to claim 33, wherein the vector is a plasmid.

35. The method to claim 33, wherein the vector is a virus.

36. The method according to claim 35, wherein the virus is an adenovirus.

37. The method according to claim 27, wherein the promoter is a constitutive eucaryotic or viral promoter.

38. The method according to claim 26, wherein the systemic administration is intravenous administration.

39. A pharmaceutical composition comprising an expression system for two neurotrophic factors.

40. A pharmaceutical composition comprising two vectors, wherein each vector comprises a nucleic acid encoding a different neurotrophic factor.

41. The pharmaceutical composition according to claim 39, wherein the expression system is a vector comprising a cassette enabling simultaneous expression of two different neurotrophic factors.

42. The pharmaceutical composition according to claim 40, wherein the vectors are viral vectors.

43. The pharmaceutical composition according to claim 42, wherein the vectors are adenovirus.

44. The pharmaceutical composition according to claim 40, wherein the vectors are plasmids.

45. The pharmaceutical composition according to claim 40, wherein the neurotrophic factors are selected from the group consisting of GDNF, BDNF, CNTF and NT3.

46. The pharmaceutical composition according to claim 45, comprising two replication defective recombinant adenoviruses, wherein one adenovirus

comprises a nucleic acid encoding CNTF and one adenovirus comprises a nucleic acid encoding GDNF.

47. The pharmaceutical composition according to claim 45, comprising two replication defective recombinant adenoviruses, wherein one adenovirus comprises a nucleic acid encoding GDNF and one adenovirus comprises a nucleic acid encoding NT3.

48. The pharmaceutical composition according to claim 45, comprising two replication defective recombinant adenoviruses, wherein one adenovirus comprises a nucleic acid encoding BDNF and one adenovirus comprises a nucleic acid encoding NT3.

49. The pharmaceutical composition according to claim 40, in intravenously injectable.

50. A pharmaceutical composition comprising an expression system encoding a neurotrophic factor and riluzole.

51. The method according to claim 26, further comprising administration of riluzole.


REMARKS

Claims 1-25 have been cancelled and rewritten as new claims 26-51, in order to conform with US patent practice. No new matter has been added.

Rhône-Poulenc Rorer Inc.
Legal-Patents #3C43
P.O. Box 5093
Collegeville, PA 19426-0997
Telephone: (610) 454-5643
Facsimile: (610) 454-3808

Dated: March 11, 1999

Respectfully submitted,


R. Keith Baker, Ph.D.
Attorney for Applicants
Registration No. 38,799